BPC-157 is not currently listed but classification is not permanent
The STEP trials, which tested semaglutide for weight loss in over 5,000 patients, documented baseline and follow-up blood pressure measurements
Unlike KPV's targeted anti-inflammatory approach, BPC-157 works as a thorough healing accelerator with a longer half-life of approximately 4-6 hours, allowing for twice-daily dosing protocols
Specific genetic polymorphisms and variations in genes related to collagen production, inflammation, and wound healing have been implicated in the disease
The conclusion at this stage is that an alternative to the current oral and IV options may be found in the acetyletaed form of glutathione, and if further analysis and clinical experiences continue to support this as a valid clinical strategy, there will be many patients very pleased to have access to such a simple strategy to enhance GSH levels where required